These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 29317233)
1. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis. Luo P; Wang X; Zhou J; Li L; Jing Z Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233 [TBL] [Abstract][Full Text] [Related]
2. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas. Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340 [TBL] [Abstract][Full Text] [Related]
3. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas. Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J J Neurosurg; 2020 Jan; 132(1):140-149. PubMed ID: 30641849 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis. Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396 [TBL] [Abstract][Full Text] [Related]
5. Chordoma: Immunohistochemical Analysis of Brachury. Sun HI; Guduk M; Gucyetmez B; Yapicier O; Pamir MN Turk Neurosurg; 2018; 28(2):174-178. PubMed ID: 28094431 [TBL] [Abstract][Full Text] [Related]
6. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma. Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674 [TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma. Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781 [TBL] [Abstract][Full Text] [Related]
10. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas. Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670 [TBL] [Abstract][Full Text] [Related]
11. Male sex as a risk factor for the clinical course of skull base chordomas. Rachinger W; Eigenbrod S; Dützmann S; Simon M; Feigl GC; Kremenevskaja N; Kretzschmar H; Zausinger S; Kreth FW; Thon N; Tonn JC J Neurosurg; 2014 Jun; 120(6):1313-20. PubMed ID: 24405075 [TBL] [Abstract][Full Text] [Related]
12. Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis. Bohman LE; Koch M; Bailey RL; Alonso-Basanta M; Lee JY World Neurosurg; 2014 Nov; 82(5):806-14. PubMed ID: 25009165 [TBL] [Abstract][Full Text] [Related]
13. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients. Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654 [TBL] [Abstract][Full Text] [Related]
14. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis. Sakai K; Hongo K; Tanaka Y; Nakayama J Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132 [TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma. Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma. Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525 [TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas. Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma. Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095 [TBL] [Abstract][Full Text] [Related]
19. Disease outcomes for skull base and spinal chordomas: a single center experience. Ahmed R; Sheybani A; Menezes AH; Buatti JM; Hitchon PW Clin Neurol Neurosurg; 2015 Mar; 130():67-73. PubMed ID: 25590662 [TBL] [Abstract][Full Text] [Related]
20. Base of skull chordomas in children and adolescents: a clinicopathologic study of 73 cases. Hoch BL; Nielsen GP; Liebsch NJ; Rosenberg AE Am J Surg Pathol; 2006 Jul; 30(7):811-8. PubMed ID: 16819322 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]